ArticleClinical journal of gastroenterology2026
Managing dual primary liver metastases from breast and colorectal cancers.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn the treatment of metastatic liver tumors, identifying the primary cancer is crucial for determining the appropriate treatment strategy. The management of colorectal liver metastases often centers around surgical resection, whereas breast cancer liver metastases are predominantly treated with chemotherapy. To our knowledge, this case represents a rare example of dual primary liver metastasis. CASE PRESENTATION: A 55-year-old female underwent systemic therapy with tamoxifen plus T-DM1 after right breast cancer resection 3 years ago. Two years ago, the patient developed simultaneous sigmoid colon cancer with liver metastasis. Due to liver damage from T-DM1, she initially underwent sigmoid colon resection, followed 2 months later by partial S5/8 resection and caudate lobectomy. S5/8 lesion was histologically diagnosed as colon cancer liver metastasis, while the caudate lobe lesion was breast cancer liver metastasis. 6 months after surgery, five liver metastases recurred, and the patient was diagnosed with liver metastatic recurrence of colorectal cancer. Six cycles of chemotherapy FOLFOX + Cetuximab were administered before surgery. The largest lesion of S5/8 shrunk, and the other four lesions were slightly enlarged. The histological examination confirmed the shrunken lesion as colorectal liver metastasis and the other lesions as breast cancer liver metastases.
conclusionAlthough radiological differentiation of metastatic liver lesions is challenging, chemotherapy response and tumor localization can aid in diagnosis. Multi-disciplinary cooperation is essential in determining treatment strategies for dual primary liver metastases.
Indexed as
Identifiers
41107652What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.